Adaptive Biotechnologies (ADPT)
(Delayed Data from NSDQ)
$4.86 USD
+0.46 (10.45%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $4.86 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth A Momentum B VGM
Price, Consensus and EPS Surprise
ADPT 4.86 +0.46(10.45%)
Will ADPT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ADPT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ADPT
Adaptive Biotechnologies (ADPT) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Tops Revenue Estimates
ADPT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Agenus (AGEN) Tanks on Colorectal Cancer Study Interim Data
TEVA's Ajovy Meets Goal in Migraine Prevention Study for Kids
Bayer (BAYRY) Meets Primary Goal in Nubeqa Expanded-Use Study
Other News for ADPT
Adaptive Biotechnologies to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Analysts Offer Insights on Healthcare Companies: CVRx (CVRX), Adaptive Biotechnologies (ADPT) and Rezolute (RZLT)
Scotiabank Sticks to Their Buy Rating for Adaptive Biotechnologies (ADPT)
Adaptive Biotechnologies (ADPT) Receives a Hold from Morgan Stanley
Adaptive Biotechnologies Corp (ADPT) Q2 2024 Earnings Call Transcript Highlights: Strong MRD ...